A Phase 3 interventional study of ER niacin/laropiprant (ERN/LRPT) and ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM) in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-02-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing simvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Simvastatin · Hypercholesterolemia.
Among the 50 studies testing simvastatin in Hypercholesterolemia, this one is the 6th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2011, is one of 26 in phase 3, and was the 42nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 50 studies testing simvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,139 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 240 across the 49 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Hypercholesterolemia by Merck & Co., Inc: 1 open now, 3 under way, 3 of them phase 3. Of 26 finished, 16 (62%) have results posted.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2011, is one of 17 in phase 3, and was the 17th registered.
Merck & Co., Inc’s Hypercholesterolemia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing simvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets (ERN/LRPT + SIM) for lowering high cholesterol and high lipid levels in the blood. The primary hypothesis is that ERN/LRPT/SIM 2 g /20 mg is equivalent to ERN/LRPT 2 g coadministered with simvastatin 20 mg in reducing low-density lipoprotein cholestrol (LDL-C).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Note: Fish oils, phytosterol margarines and other non-prescribed therapies are allowed provided participant has been on a stable dose for 6 weeks prior to Visit 2 and agrees to remain on this dose for the duration of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
Drug: ER niacin/laropiprant (ERN/LRPT) · Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM) · Drug: Simvastatin (SIM) · Drug: Placebo Run-In · Drug: SIM-matching placebo
Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
Drug: ER niacin/laropiprant (ERN/LRPT) · Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM) · Drug: Simvastatin (SIM) · Drug: Placebo Run-In · Drug: SIM-matching placebo
Drug page: MK-0524B
ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
Also known as: MK-0524B
ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
Also known as: MK-0524A, Tredaptive™
Simvastatin 10 mg oral tablet taken once daily
Also known as: Zocor®
Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
Placebo for simvastatin 10 mg oral tablet taken once daily
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels
Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.
Time frame: Baseline and Week 12 and Week 20
Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels
Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.
Time frame: Baseline and Week 12 and Week 20
| Milestone | ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1) | ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2) |
|---|---|---|
| Started | 577 | 562 |
| Completed | 84 | 83 |
| Not completed | 493 | 479 |
| Withdrew: Adverse event | 63 | 43 |
| Withdrew: Noncompliance with study drug | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Withdrawal by subject | 9 | 4 |
| Withdrew: Study terminated by sponsor | 406 | 415 |
| Withdrew: Protocol violation | 9 | 10 |
| Withdrew: Physician decision | 2 | 1 |
| Milestone | ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1) | ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2) |
|---|---|---|
| Started | 84 | 83 |
| Completed | 6 | 4 |
| Not completed | 78 | 79 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Study terminated by sponsor | 77 | 76 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.
No measurements were reported for this outcome.
Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.
No measurements were reported for this outcome.
Collected over Up to 22 weeks, including 14 days after last dose of study drug (non-serious adverse events up to 20 weeks and serious adverse events up to 22 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Seq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA | — | 11/567 (1.9%) | 103/567 (18.2%) |
| Seq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIM | — | 5/554 (0.9%) | 95/554 (17.1%) |
| Seq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA | — | 0/83 (0%) | 0/83 (0%) |
| Seq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM | — | 1/82 (1.2%) | 0/82 (0%) |
| Event | Seq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA | Seq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIM | Seq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA | Seq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM |
|---|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/567 | 0/554 | 0/83 | 1/82 |
| FlushingVascular disorders | 1/567 | 2/554 | 0/83 | 0/82 |
| Arteriospasm coronaryCardiac disorders | 0/567 | 1/554 | 0/83 | 0/82 |
| Coronary artery diseaseCardiac disorders | 0/567 | 1/554 | 0/83 | 0/82 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/567 | 1/554 | 0/83 | 0/82 |
| Angina pectorisCardiac disorders | 1/567 | 0/554 | 0/83 | 0/82 |
| Abdominal discomfortGastrointestinal disorders | 1/567 | 0/554 | 0/83 | 0/82 |
| Gastrointestinal disorderGastrointestinal disorders | 1/567 | 0/554 | 0/83 | 0/82 |
| Non-cardiac chest painGeneral disorders | 1/567 | 0/554 | 0/83 | 0/82 |
| PneumoniaInfections and infestations | 1/567 | 0/554 | 0/83 | 0/82 |
| Event | Seq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA | Seq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIM | Seq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA | Seq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM |
|---|---|---|---|---|
| FlushingVascular disorders | 78/567 | 72/554 | 0/83 | 0/82 |
| PruritusSkin and subcutaneous tissue disorders | 39/567 | 29/554 | 0/83 | 0/82 |
| Age, Continuous(Years) | ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1) | ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2) | Total |
|---|---|---|---|
| Mean | 56.2 ± 10.44 | 56.4 ± 10.44 | 56.3 ± 10.43 |
| Sex: Female, Male(Participants) | ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1) | ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2) | Total |
|---|---|---|---|
| Female | 345 | 332 | 677 |
| Male | 232 | 230 | 462 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from May 2011 to primary completion in Jan 2012, 8 months.
Results were first posted in Jun 2016, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MK-0524B · Simvastatin